Systemic Effects of Phosphodiesterase Type 5 Inhibitors Beyond Erectile Dysfunction: A Narrative Review
Authors:
- Wiktor DaniszewskiWDWiktor Daniszewski
- Wiktoria KnobelsdorfWKWiktoria Knobelsdorf
- Gabriela FurtakGFGabriela Furtak
- Maria ŁagódkaMŁMaria Łagódka
- Michał PogodaMPMichał Pogoda
- Katarzyna ZającKZKatarzyna Zając
- Dominika PietrzykDPDominika Pietrzyk
- Bartosz OderBOBartosz Oder
- Maciej ĆmilMĆMaciej Ćmil
- Wojciech KarchutWKWojciech Karchut
Open Access
- 2 December 2025
- journal article
- Published by Asosiasi Asesmen Pendidikan (AAP) in JITSS (Journal of Innovation and Trend in Social Sciences)
- Vol. 2 (2) , 87-100
Abstract
Phosphodiesterase type 5 inhibitors (PDE5Is) are widely prescribed for erectile dysfunction; however, growing evidence indicates that their pharmacological effects extend beyond urological indications and involve multiple organ systems. This narrative review aims to synthesize and critically evaluate current evidence on the systemic effects of PDE5 inhibitors across cardiovascular, renal, neurological, and urological domains, as well as emerging therapeutic indications. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science for studies published up to May 2024, including preclinical studies, clinical trials, observational studies, systematic reviews, and meta-analyses. The reviewed evidence demonstrates that PDE5 inhibitors are associated with reduced cardiovascular morbidity and mortality, improvements in cardiac and pulmonary hemodynamics, preservation of renal function in diabetic populations, potential neuroprotective effects against cognitive decline and ischemic stroke, and symptomatic improvement in benign prostatic hyperplasia and lower urinary tract symptoms. Additional benefits have been reported in conditions characterized by vascular dysfunction, such as angina pectoris and Raynaud’s phenomenon. Overall, PDE5 inhibitors represent a pharmacologically versatile drug class with clinically relevant systemic effects beyond erectile dysfunction, supporting their potential role as adjunctive therapies in broader disease management, although further well-designed randomized controlled trials are needed to inform clinical guidelines.Keywords
This publication has 29 references indexed in Scilit:
- An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitorsMolecular Diversity, 2024
- Phosphodiesterase-5 inhibitors use and the risk of alzheimer's disease: a systematic review and meta-analysisNeurological Sciences, 2024
- Advances in targeting Phosphodiesterase 1: From mechanisms to potential therapeuticsEuropean Journal of Medicinal Chemistry, 2023
- The potential therapeutic effect of phosphodiesterase 5 inhibitors in the acute ischemic stroke (AIS)Molecular and Cellular Biochemistry, 2023
- PDE5 inhibitors against synaptic and cognitive impairment in Alzheimer’s disease and related dementiaAlzheimer's & Dementia, 2022
- Erectile dysfunction, phosphodiesterase-5 inhibitor use and risk of cardiovascular disease and mortality in people with diabetes: A systematic review and meta-analysisPrimary Care Diabetes, 2022
- Sildenafil reduces the incidence of Alzheimer’s diseaseAlzheimer's & Dementia, 2021
- Pharmacotherapy Options in the Management of Raynaud’s PhenomenonCurrent Treatment Options in Rheumatology, 2018
- Tadalafil enhances working memory, and reduces hippocampal oxidative stress in both young and aged miceEuropean Journal of Pharmacology, 2014
- Vardenafil for the Treatment of Raynaud Phenomenon: A Randomized, Double-blind, Placebo-Controlled Crossover StudyArchives of internal medicine (1960), 2012